Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer
Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures. These molecules may be used as single or combination therapy for patients with advanced disease to prevent and treat metastatic spread.
Materials provided by Elsevier. Note: Content may be edited for style and length.
Source link aaaaa
